Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Cellectis S.A. (CLLS)

2.4   0.05 (2.13%) 11-28 09:33
Open: 2.42 Pre. Close: 2.35
High: 2.43 Low: 2.4
Volume: 9,819 Market Cap: 109(M)

Technical analysis

as of: 2022-11-28 9:17:25 AM
Stoxline posted a BUY today, downgraded from strong buy. Upward movement continues, but could change at any time.
Target: Six months: 3.09     One year: 3.61
Support: Support1: 2.24    Support2: 2
Resistance: Resistance1: 2.65    Resistance2: 3.09
Pivot: 2.26
Moving Average: MA(5): 2.28     MA(20): 2.32
MA(100): 2.77     MA(250): 4.09
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 64.5     %D(3): 48.6
RSI: RSI(14): 49.9
52-week: High: 9.56  Low: 2
Average Vol(K): 3-Month: 83 (K)  10-Days: 97 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ CLLS ] has closed below upper band by 28.6%. Bollinger Bands are 47.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.42 - 2.44 2.44 - 2.45
Low: 2.31 - 2.32 2.32 - 2.33
Close: 2.33 - 2.35 2.35 - 2.37

Company Description

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Headline News

Fri, 25 Nov 2022
Cellectis (NASDAQ:CLLS) Rating Lowered to Sell at - MarketBeat

Fri, 25 Nov 2022
News focus: Clock is ticking for legal clarity on digital securities - Law Gazette

Sun, 20 Nov 2022
Five People Dead After Gay Club Shooting in Colorado Springs - msnNOW

Thu, 10 Nov 2022
Cellectis Presents Pre-Clinical Data on TALENĀ®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022 - Yahoo Finance

Mon, 07 Nov 2022
GSE loan limits in high-cost areas will exceed $1M in 2023 - National Mortgage News

Fri, 04 Nov 2022
Iovance's (IOVA) Q3 Earnings Beat Estimates, Revenues Nil - Nasdaq

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 46 (M)
Shares Float 34 (M)
% Held by Insiders 0 (%)
% Held by Institutions 23.4 (%)
Shares Short 580 (K)
Shares Short P.Month 723 (K)

Stock Financials

EPS -2.96
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3
Profit Margin (%) 0
Operating Margin (%) -601.5
Return on Assets (ttm) -24.1
Return on Equity (ttm) -55.8
Qtrly Rev. Growth -82.4
Gross Profit (p.s.) 0.75
Sales Per Share 0.48
EBITDA (p.s.) -2.7
Qtrly Earnings Growth 0
Operating Cash Flow -107 (M)
Levered Free Cash Flow -55 (M)

Stock Valuations

PE Ratio -0.8
PEG Ratio 0
Price to Book value 0.78
Price to Sales 4.82
Price to Cash Flow -1

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.